⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK